Premium
Sangamo Therapeutics Inc (0R1D)
LSE
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-25 | Mr. Nikunj JainInterim CFO and Principal Financial & Accounting Officer | -1,92k | 334,48 | Sale to Issuer | 0,17 | 202,66k | -0,94% |
| 2026-05-25 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -4,04k | 703,47 | Sale to Issuer | 0,17 | 568,62k | -0,70% |
| 2026-05-25 | Dr. Alexander D. MacraeCEO, President & Director | -12,61k | 2,20k | Sale to Issuer | 0,17 | 1,65M | -0,76% |
| 2026-05-25 | Dr. Gregory DavisHead of Research & Technology | -1,63k | 284,11 | Sale to Issuer | 0,17 | 81,02k | -1,97% |
| 2026-05-25 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -4,04k | 703,47 | Sale to Issuer | 0,17 | 249,98k | -1,59% |
| 2026-04-22 | Dr. Gregory DavisHead of Research & Technology | -69,83k | 17,69k | Vente | 0,25 | 77,99k | -47,24% |
| 2026-04-21 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -345,94k | 89,18k | Vente | 0,26 | 242,77k | -58,76% |
| 2026-02-24 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -14,42k | 6,78k | Sale to Issuer | 0,47 | 588,71k | -2,39% |
| 2026-02-24 | Dr. Alexander D. MacraeCEO, President & Director | -38,93k | 18,31k | Sale to Issuer | 0,47 | 1,63M | -2,34% |
| 2026-02-24 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -14,00k | 6,59k | Sale to Issuer | 0,47 | 561,41k | -2,43% |
| 2026-02-24 | Mr. Nikunj JainInterim CFO and Principal Financial & Accounting Officer | -5,79k | 2,72k | Sale to Issuer | 0,47 | 199,92k | -2,81% |
| 2026-02-24 | Dr. Gregory DavisHead of Research & Technology | -5,95k | 2,80k | Sale to Issuer | 0,47 | 147,82k | -3,87% |
| 2026-01-22 | Mr. Nikunj JainInterim CFO and Principal Financial & Accounting Officer | -7,72k | 3,08k | Sale to Issuer | 0,40 | 180,62k | -4,10% |
| 2026-01-22 | Ms. Prathyusha DuraibabuInitié | -36,68k | 14,62k | Sale to Issuer | 0,40 | 535,03k | -6,42% |
| 2026-01-22 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -36,68k | 14,62k | Sale to Issuer | 0,40 | 541,40k | -6,34% |
| 2026-01-22 | Dr. Alexander D. MacraeCEO, President & Director | -102,95k | 41,03k | Sale to Issuer | 0,40 | 1,56M | -6,20% |
| 2026-01-22 | Dr. Gregory DavisHead of Research & Technology | -7,72k | 3,08k | Sale to Issuer | 0,40 | 139,31k | -5,25% |
| 2026-01-22 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -36,68k | 14,62k | Sale to Issuer | 0,40 | 568,12k | -6,06% |
| 2025-11-24 | Mr. Nikunj JainInterim CFO and Principal Financial & Accounting Officer | -578,00 | 240,79 | Sale to Issuer | 0,42 | 245,72k | -0,23% |
| 2025-11-24 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -2,04k | 847,78 | Sale to Issuer | 0,42 | 566,95k | -0,36% |
| 2025-11-24 | Dr. Alexander D. MacraeCEO, President & Director | -7,49k | 3,12k | Sale to Issuer | 0,42 | 1,63M | -0,46% |
| 2025-11-24 | Ms. Prathyusha DuraibabuInitié | -2,54k | 1,06k | Sale to Issuer | 0,42 | 560,58k | -0,45% |
| 2025-11-24 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -2,54k | 1,06k | Sale to Issuer | 0,42 | 583,66k | -0,43% |
| 2025-11-24 | Dr. Gregory DavisHead of Research & Technology | -723,00 | 301,20 | Sale to Issuer | 0,42 | 139,70k | -0,51% |
| 2025-10-22 | Mr. Nikunj JainInterim CFO and Principal Financial & Accounting Officer | -6,71k | 4,43k | Sale to Issuer | 0,66 | 246,30k | -2,65% |
| 2025-10-22 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -44,12k | 29,12k | Sale to Issuer | 0,66 | 487,04k | -8,31% |
| 2025-10-22 | Dr. Alexander D. MacraeCEO, President & Director | -126,95k | 83,79k | Sale to Issuer | 0,66 | 1,40M | -8,30% |
| 2025-10-22 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -43,74k | 28,87k | Sale to Issuer | 0,66 | 503,27k | -8,00% |
| 2025-10-22 | Ms. Prathyusha DuraibabuInitié | -45,23k | 29,85k | Sale to Issuer | 0,66 | 480,18k | -8,61% |
| 2025-10-22 | Dr. Gregory DavisHead of Research & Technology | -6,71k | 4,43k | Sale to Issuer | 0,66 | 103,25k | -6,10% |
| 2025-08-24 | Dr. Alexander D. MacraeCEO, President & Director | -7,49k | 4,39k | Sale to Issuer | 0,59 | 1,28M | -0,58% |
| 2025-08-24 | Dr. Gregory DavisHead of Research & Technology | -723,00 | 423,89 | Sale to Issuer | 0,59 | 109,95k | -0,65% |
| 2025-08-24 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -1,43k | 840,75 | Sale to Issuer | 0,59 | 442,10k | -0,32% |
| 2025-08-24 | Ms. Prathyusha DuraibabuInitié | -1,79k | 1,05k | Sale to Issuer | 0,59 | 436,34k | -0,41% |
| 2025-08-24 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -1,79k | 1,05k | Sale to Issuer | 0,59 | 457,94k | -0,39% |
| 2025-07-22 | Dr. Alexander D. MacraeCEO, President & Director | -126,95k | 60,91k | Sale to Issuer | 0,48 | 1,27M | -9,07% |
| 2025-07-22 | Ms. Prathyusha DuraibabuInitié | -31,87k | 15,29k | Sale to Issuer | 0,48 | 433,12k | -6,85% |
| 2025-07-22 | Mr. Scott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary | -31,87k | 15,29k | Sale to Issuer | 0,48 | 439,53k | -6,76% |
| 2025-07-22 | Dr. Nathalie Dubois-StringfellowSenior VP & Chief Development Officer | -31,87k | 15,29k | Sale to Issuer | 0,48 | 454,73k | -6,55% |
| 2025-07-22 | Dr. Gregory DavisHead of Research & Technology | -6,71k | 3,22k | Sale to Issuer | 0,48 | 108,65k | -5,81% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
